Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Southeast Clinical Research Associates, LLC
Study ID
NCT03059277
Phase
PHASE4
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine the efficacy of intravitreal aflibercept injections administered in a treat and extend fashion in eyes that have persistent center involved diabetic macular edema following at least 4 intravitreal injections of 0.3 mg ranibizumab over 24 weeks.

Key Dates

Start date
Jun 1, 2018
Status verified
Jun 2018
Primary completion
Jun 30, 2020
Completion
Sep 30, 2020

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intravitreal Aflibercept
    Intravitreal Aflibercept Injection (IAI)

Primary Outcome Measure

Change in Central Subfield Thickness (CST) [ Time Frame: 52 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Charlotte Eye Ear Nose and Throat Associates, PACharlotteNorth Carolina28210-
Charlotte Eye Ear Nose and Throat Associates, PAStatesvilleNorth Carolina28677-

Find similar trials in Charlotte, NC

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
Charlotte Eye Ear Nose and Throat Associates, PA· Charlotte, NCCharlotte Eye Ear Nose and Throat Associates, PA· Statesville, NC

Related Studies